Study: U.S. provides faster access to oncology drugs than Europe

Thursday, July 12, 2012 11:01 AM

Cancer patients in the U.S. get faster access to more oncology drugs to treat their disease than patients in Europe, according to a recent study by the Boston-based Tufts Center for the Study of Drug Development.

In addition, the study found new oncology drug approvals in the U.S. outpaced European approvals by 33% between 2000 and 2011.

"While greater access to more treatment options is definitely a positive for patients in the U.S., it is not clear if greater access leads to better health outcomes," said Joshua P. Cohen, the research assistant professor at Tufts CSDD who conducted the analysis.

Cohen said the growing use of comparative effectiveness research, which provides information on the relative strengths and weaknesses of different medical technologies, could help close the gap between what is known and what is done in pharmaceutical care.

"Although more oncology drugs are available in the U.S., and the costs for a higher share of them are reimbursed, the evidence-based approach adopted by European systems have improved the affordability of drugs in Europe that are considered to be cost-effective," Cohen said.

Other findings of the study were:

  • Between 2000 and 2011, 40 oncology drugs received market approval in the U.S. compared to 30 in Europe.
  • Oncology drug prices in Europe, on average, are 9% lower than in the U.S.
  • Patient cost sharing is much lower in Europe than the U.S., where the average co-insurance rate per covered drug is 33%.
Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs